Lexaria Bioscience (LEXX) Q4 2025 earnings summary

Executive summary

• DehydraTECH technology enhances bioavailability of APIs, focusing on GLP-1/GIP drugs, CBD, and other molecules for diabetes, weight loss, and hypertension applications.

• Fiscal 2025 saw significant R&D progress, including animal and human studies on DehydraTECH-enhanced drugs and the completion of a 12-week chronic human clinical trial.

• Six new patents were granted, expanding IP protection in epilepsy, diabetes, nicotine, and food products.

• The company continues to seek commercial partnerships and licensing opportunities for DehydraTECH.

Financial highlights

• Fiscal 2025 revenue increased 52% year-over-year to $705,923, mainly from technology licensing.

• Net loss from operations rose to $11.9 million from $5.8 million in 2024, driven by a 249% increase in R&D expenses to $8.2 million.

• General and administrative expenses increased 13% to $4.3 million, with higher wages, stock-based compensation, and insurance premiums.

• Cash used in operating activities was $10.5 million, with $1.8 million in cash and equivalents at year-end.

• Working capital decreased to $2.0 million from $6.8 million year-over-year.

Outlook and guidance

• Revenue from technology licensing is expected to decrease in fiscal 2026 due to the expiration of a key license agreement.

• R&D expenses are anticipated to decrease in 2026 unless new financing is secured.

• The company will require additional funding or partnerships to continue operations and advance clinical programs.

• Management has determined there is substantial doubt about the ability to continue as a going concern without new capital.